InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,277.51
(
0.80%
)
US TECH 100
18,064.80
(
0.02%
)
Dow Jones
38,686.32
(
1.51%
)
Brent Oil
81.30
(
0.00%
)
Bitcoin
67,594.11
(
0.17%
)
Post# of 3687
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

mrgoodtrade

Send PM Follow Ignore
Followers 215
Posts 17899
Boards Moderated 0
Alias Born 01/23/2003

mrgoodtrade

Member Level

Re: mrgoodtrade post# 1887

Wednesday, 12/18/2013 9:24:23 AM

Wednesday, December 18, 2013 9:24:23 AM

Post# of 3687

Dr. Michael Lonsert , Chief Investment Officer, Nutraceuticals, Adiuvo Investment said, " ImmuDyne has filed two new provisional patents - one in the adjuvant treatment of bladder cancer and one in treatment of alcohol abuse. Clinical testing on each indication will commence in Q1 2014. Moreover, in addition to these two indications, the JV anticipates the filing of several new patents in the first quarter of 2014, with clinical testing on each indication taking place in each instance as well. One of the key things that Adiuvo brings to the JV is funding, including research grants, enabling ImmuDyne , and the JV, to have access to a robust R&D budget."

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up